Epilepsy – Landscape & Forecast – Disease Landscape & Forecast

Epilepsy, which afflicts approximately 4.7 million people in the major markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s seizure syndrome and seizure type. The market is heavily genericized, and most of the anti-epileptic drugs (AEDs) can be used as monotherapies or in combination. However, recent entrants like cenobamate, fenfluramine, and ganaxolone are carving share in the market, despite being high-priced branded products, by targeting underserved and orphan epilepsy populations. This report provides a detailed account of dynamics in this complex market, including the continued dominance of second-generation AEDs while emerging therapies nevertheless gain traction by addressing unmet needs in this diverse patient population.

Questions answered

  • What is the current size of epilepsy market by country, and how do we forecast the market will evolve in the coming years?
  • What key factors will shape the future market, and what drivers and barriers will influence the use of key AEDs? Will the dominance of second-generation therapies continue, and which third-generation therapies will be successful over our forecast period?
  • How will high-priced third-generation AEDs fare in this highly genericized market?
  • How have UCB’s Nayzilam and Neurelis’s Valtoco been integrated into the treatment algorithm?
  • What are the unmet needs in the current epilepsy treatment paradigm? How will emerging therapies address these unmet needs?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Approximately 20 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.

Epidemiology: Diagnosed prevalence of epilepsy by country, segmented by generalized and partial-onset seizures; drug-treated cases.

Emerging therapies: Phase II: 12 drugs; Phase III / preregistration: 6 drugs.

Market forecast features: Patient-based market forecast extending through 2032, segmented by brands and generics / biosimilars.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports